FDA Approves Pembrolizumab for PD-L1+ Gastric Cancer

September 22, 2017 – The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- and platinum-containing chemotherapy, and, if appropriate, HER2/neu-targeted therapy. The approval is based on findings from the phase II KEYNOTE-059 study. In the study, 143 of 259 patients … (leggi tutto)